For patients with newly diagnosed unmutated CLL how will you decide between BTKi alone vs Ven/BTKi vs Ven/Obin vs Ven/Obin/Acalabrutinib?  

First, as with all CLL patients, we would discuss the benefits and risks of fixed-duration vs continuous BTKi therapy, here with the likelihood that fixed duration treatment might have shorter remission durations after initial treatment, but with the unknown duration of response with retreatment. If...

In the absence of head-to-head, prospective trial data (which we will soon see with ongoing trials such as MAJIC comparing AV and VenO + MRD-guided duration of therapy), we must fall back on our precautionary principles and try to minimize risk for patients while maximizing benefits. This means havi...